COPD is/is not a systemic disease? / Claudio F. Donner, editor.

Format:

Book

Contributor:

Donner, C. F. (Claudio F.)

Series:

Public health in the 21st century series.

Public health in the 21st century series

Language:

English

Subjects (All):

Lungs--Diseases, Obstructive.

Lungs.

Lungs--Diseases, Obstructive--Complications.

Inflammation.

Physical Description:

1 online resource (296 p.)

Edition:

1st ed.

Place of Publication:

New York : Nova Biomedical Books, c2010.

Language Note:

English

Summary:

Although COPD is a major disease world-wide, there is a perplexing current uncertainty about the nature of this disease. This work explores what the pathogenesis of this respiratory disease is and much more.

Contents:

Intro

COPD IS/IS NOT A SYSTEMIC DISEASE?

CONTENTS

INTRODUCTION

Chapter 1 COPD IS A SYSTEMIC DISEASE - THE PATHPHYSIOLOGICAL BASIS

ABSTRACT

Systemic Inflammation

Genetics and Epigenetics

Vascular Abnormalities

Immunology

Repair Failure

Infections

CONCLUSION

REFERENCES

Chapter 2 COPD IS NOT A SYSTEMIC DISEASE - THE PATHOPHYSIOLOGICAL BASIS

DIAGNOSIS AND STAGING OF COPD

PATHOPHYSIOLOGY

Small Airways Disease

Pulmonary Hyperinflation

Ventilation-perfusion

Chapter 3 DISCUSSION ON THE PATHOPHYSIOLOGICAL BASIS OF COPD

Chapter 4 COPD AND SYSTEMIC INFLAMMATION: MYTH OR REALITY? REALITY

Origin of Systemic Inflammation in COPD

Consequences of systemic inflammation in COPD

Chapter 5 COPD AND SYSTEMIC INFLAMMATION: MYTH OR REALITY? MYTH

GENERAL CONSIDERATIONS

SMOKING AND 'SYSTEMIC INFLAMMATION'

STABLE COPD AND 'SYSTEMIC INFLAMMATION'

ACUTE EXACERBATIONS AND 'SYSTEMIC INFLAMMATION'

THE EFFECT OF COPD TREATMENT ON 'SYSTEMIC INFLAMMATION'

Chapter 6 DISCUSSION ON COPD AND SYSTEMIC INFLAMMATION: MYTH OR REALITY?

Chapter 7 BIOMARKERS OF SYSTEMIC INVOLVEMENT IN STABLE COPD: DO THEY EXIST? YES

PULMONARY BIOMARKERS IN STABLE COPD

SYSTEMIC INVOLVEMENT IN COPD

BIOMARKERS OF SYSTEMIC INVOLVEMENT IN STABLE COPD: MORE THAN SYSTEMIC INFLAMMATION

BIOMARKERS OF SYSTEMIC INVOLVEMENT IN COPD: HOW TO PROGRESS? LESSONS LEARNED FROM HEART FAILURE

BIOMARKERS OF SYSTEMIC INVOLVEMENT IN STABLE COPD: HOW TO PROGRESS?

a. CC-16

b. Surfactant Protein D (SP-D)

c. Cachexia

d. Osteoporosis

CONCLUSION.

REFERENCES

Chapter 8 BIOMARKERS OF SYSTEMIC INOLVEMENT IN STABLE COPD: DO THEY EXIST? NO

Inflammation in COPD Concomitant Diseases

The Role of "Inflammaging"

Systemic Biomarkers Involvement in COPD

The Controversial Meaning of Steroid Therapy in COPD

Lung Specific Biomarkers in COPD: New Frontiers?

Chapter 9 DISCUSSION ON BIOMARKERS OF SYSTEMIC INVOLVEMENT IN STABLE COPD: DO THEY EXIST?

Chapter 10 DISCUSSION IN-DEPTH OF TOPICS PRESENTED IN THE MORNING, WITH A VIEW TO REACHING A CONSENSUS OR DISSENSUS

I. PATHOPHYSIOLOGICAL BASIS

II. COPD AND SYSTEMIC INFLAMMATION: MYTH OR REALITY?

III. BIOMARKERS OF SYSTEMIC INVOLVEMENT IN STABLE COPD - DO THEY EXIST?

Chapter 11 BIOMARKERS OF SYSTEMIC INVOLVEMENT IN ACUTE EXACERBATIONS OF COPD: IS THERE OVERWHELMING EVIDENCE? YES

1. WHAT IS AN EXACERBATION OF COPD?

2. WHAT IS A BIOMARKER?

3. SYSTEMIC INVOLVEMENT AT EXACERBATION OF COPD

4. WHAT DO WE WANT A SYSTEMIC EXACERBATION BIOMARKER TO ASSESS?

5. HOW SHOULD WE ASSESS THE EFFICACY OF A BIOMARKER IN ACHIEVING THESE AIMS?

6. A BIOMARKER TO CONFIRM EXACERBATION?

7. A BIOMARKER TO INFORM ON EXACERBATION AETIOLOGY?

8. A BIOMARKER TO INFORM ON EXACERBATION SEVERITY?

9. A BIOMARKER TO PREDICT POST-EXACERBATION EVENTS?

Chapter 12 IS THERE EVIDENCE FROM BIOMARKERS OF SYSTEMIC INVOLVEMENT IN COPD EXACERBATIONS? NO

a) Underlying Baseline Inflammation due to Comorbid Conditions

b) Etiology of Exacerbations

c) Impact of Treatment

Chapter 13 DISCUSSION ON: IS THERE OVERWHELMING EVIDENCE FROM BIOMARKERS OF SYSTEMIC INVOLVEMENT IN COPD EXACERBATIONS?.

Chapter 14 SCIENCE AT THE BEDSIDE. IS COPD A RESPIRATORY DISEASE WITH PROMINENT SYSTEMIC IMPLICATIONS OR A SYSTEMIC DISEASE WITH PULMONARY SYMPTOMS? COPD - A PRIMARILY RESPIRATORY DISEASE WITH IMPORTANT SYSTEMIC CONSEQUENCES

SYSTEMIC INFLAMMATION

Acute Phase Proteins

CRP

COPD AND IMPAIRED FUNCTIONAL CAPACITY

Pulmonary Factors

Systemic Factors

MUSCLE DYSFUNCTION AND MALNUTRITION IN COPD

Mechanisms

Treatment

CARDIOVASCULAR DISEASE

Coronary Artery Disease and Atherosclerosis

Heart Failure

Pulmonary Arterial Hypertension

Cardiac Function at Rest

Cardiac Function During Exercise

Arterial Stiffness and Endothelial Function

ANEMIA

OSTEOPOROSIS

Therapy

DEPRESSION

LUNG CANCER

OBSTRUCTIVE SLEEP APNOEA

IMPLICATIONS FOR THERAPY

Chapter 15 SCIENCE AT THE BEDSIDE. IS COPD A RESPIRATORY DISEASE WITH PROMINENT SYSTEMIC IMPLICATIONS OR A SYSTEMIC DISEASE WITH PULMONARY SYMPTOMS? A CASE REPORT

CASE REPORT

THE CASE FOR CONSIDERING COPD AS A SYSTEMIC DISEASE WITH PROMINENT RESPIRATORY MANIFESTATIONS

Mrs. CG

PROMINENT SYSTEMIC DISEASE AND PREDICTABLE CO-MORBIDITY IN COPD

COPD AND SYSTEMIC INFLAMMATION

An Inflammatory Respiratory Disease with Systemic Spill-over

A Systemic Disease Involving Primarily the Lungs

A Vicious Circle

SYSTEMIC INFLAMMATION IN STABLE COPD

SYSTEMIC INFLAMMATION AND ITS EFFECT ON THE TREATMENT OF MRS. CG

SUMMARY

Chapter 16 DISCUSSION ON: IS COPD A RESPIRATORY DISEASE WITH PROMINENT SYSTEMIC IMPLICATIONS OR A SYSTEMIC CONDITION WITH PULMONARY SYMPTOMS?

Chapter 17 APPROACH TO COPD: RESPIRATORY OR SYSTEMIC TREATMENT? RESPIRATORY APPROACH

REFERENCES.

Chapter 18 APPROACH TO COPD: RESPIRATORY OR SYSTEMIC TREATMENT? SYSTEMIC APPROACH

COMPLEX CHRONIC COMORBIDITIES

CLINICAL GUIDELINES FOR CORD AND CHRONIC DISEASES

EFFECTS OF TREATMENT OF CORD ON ITS COMORBIDITIES

Smoking Cessation

Rehabilitation

Supplemental Oxygen Therapy

Pharmacologic Treatment

EFFECT OF TREATMENT OF COMORBIDITIES ON COPD

Statins

-Blockers

Chapter 19 DISCUSSION ON THE APPROACH TO COPD: RESPIRATORY OR SYSTEMIC TREATMENT?

Chapter 20 GUIDELINES AND CLINICAL PRACTICE: MYTH OR REALITY? - MYTH

MYTH 1: STEPWISE APPROACH TO TREATMENT OF COPD

MYTH 2: SHORT-ACTING BRONCHODILATOR FOR MILD COPD

MYTH 3: INHALED CORTICOSTEROIDS FOR SEVERE COPD

TREATMENT OF COPD ACCORDING TO THE PATIENT CHARACTERISTICS

THE REASON FOR THE CONFUSION

Chapter 21 GUIDELINES AND CLINICAL PRACTICE: MYTH OR REALITY? - REALITY

Source of Guidelines

Methods

Conflicts of Interest

COPD GUIDELINES

Reality or Myth

Systemic Features and COPD Guidelines

IMPACT OF GUIDELINES IN PATIENTS WITH CO-MORBIDITIES

Chapter 22 DISCUSSION ON: GUIDELINES AND CLINICAL PRACTICE: MYTH OR REALITY?

Chapter 23 DISCUSSION IN-DEPTH OF TOPICS PRESENTED IN THE AFTERNOON, WITH A VIEW TO REACHING A CONSENSUS OR DISSENSUS

IV. BIOMARKERS OF SYSTEMIC INVOLVEMENT IN ACUTE EXACERBATIONS OF COPD: IS THERE OVERWHELMING EVIDENCE?

V. APPROACH TO COPD: RESPIRATORY OR SYSTEMIC TREATMENT?

VI. GUIDELINES AND CLINICAL PRACTICE

GOALS OF CLINICAL PRACTICE GUIDELINES

PROBLEMS WITH CURRENT COPD GUIDELINES

Chapter 24 SUMMING UP AND FINAL REMARKS

INDEX.

Notes:

Description based upon print version of record.

Includes bibliographical references and index.

Description based on print version record.

ISBN:

1-61668-722-3

OCLC:

923661713